Status:

TERMINATED

GALLEX 1 - Long Term Extension Study in Patients With Type 2 Diabetes

Lead Sponsor:

AstraZeneca

Conditions:

Type 2 Diabetes

Eligibility:

All Genders

18+ years

Phase:

PHASE3

Brief Summary

This is a 107-week open-label, multi-center long-term extension study from GALLANT studies 2/22, 5, 7, 8 and 14 to monitor the safety and tolerability of oral tesaglitazar 1 mg in patients with type 2...

Eligibility Criteria

Inclusion

  • Provision of a written informed consent
  • Men or women who are \>=18 years of age
  • Female patients: postmenopausal, hysterectomized, or if of childbearing potential, using a reliable method of birth control
  • Completed the last two visits of randomized treatment period in GALLANT 2/22, 5, 7, 8 or 14 studies.

Exclusion

  • Type 1 diabetes
  • New York Heart Association heart failure Class III or IV
  • Treatment with chronic insulin
  • History of hypersensitivity or intolerance to any peroxisome proliferator-activated receptor agonist (like Actos or Avandia), fenofibrate, metformin or 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (statin)
  • History of drug-induced myopathy or drug-induced creatine kinase elevation, liver enzyme elevations, neutropenia (low white blood cells)
  • Creatinine levels above twice the normal range
  • Creatine kinase above 3 times the upper limit of normal
  • Previous enrollment in this long-term extension study
  • Any clinically significant abnormality identified on physical examination, laboratory tests or electrocardiogram, which in the judgment of the investigator would compromise the patient's safety or successful participation in the clinical study

Key Trial Info

Start Date :

March 1 2005

Trial Type :

INTERVENTIONAL

End Date :

January 1 2007

Estimated Enrollment :

2000 Patients enrolled

Trial Details

Trial ID

NCT00252876

Start Date

March 1 2005

End Date

January 1 2007

Last Update

March 17 2008

Active Locations (277)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 70 (277 locations)

1

Research Site

Birmingham, Alabama, United States

2

Research Site

Columbiana, Alabama, United States

3

Research Site

Mobile, Alabama, United States

4

Research Site

Carlisle, Arkansas, United States